Search Results 661-670 of 18594 for alopecia

1. A Study Of CA-4948 In Patients With Relapsed Or Refractory Primary Central Nervous System Lymphoma - Mayo Clinic

   Presence of an acute or chronic toxicity resulting from prior anti-cancer therapy, with the exception of alopecia, that has not resolved to Grade ≤ 1 ...

2. A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

   Ongoing toxic manifestations of previous treatments > Grade 2 with the exception of alopecia and neuropathy. Subjects with treated brain metastases with ...

3. A Study of ASTX660 Alone or Combined with ASTX727 in Subjects with Relapsed/Refractory Acute Myeloid Leukemia (AML) - Mayo Clinic

   ... alopecia). Hypersensitivity to decitabine, ASTX727, ASTX660, or any of their excipients. Liver cirrhosis, or chronic liver disease Child-Pugh Class B or C ...

4. Nemvaleukin Alfa (ALKS 4230) Monotherapy In Patients With Advanced Cutaneous Melanoma Or Advanced Mucosal Melanoma - Mayo Clinic

   ... alopecia are acceptable assuming all other inclusion criteria are met]). Patient who has received prior systemic anti-neoplastic agent(s) must wait at least ...

5. A Study Comparing Gemcitabine With Or Without AZD 1775 In Treating Patients With Recurrent Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer - Mayo Clinic

   ... alopecia or peripheral neuropathy can also be included; Palliative radiation to < 10% of bone marrow is permissible if completed within one week of ...

6. A Phase 2 Study Of ONC206 In Advanced Pheochromocytoma And Paraganglioma - Mayo Clinic

   Has unresolved toxicities from previous locoregional, systemic, or any other therapies, defined as toxicities (other than Grade ≤2 neuropathy or alopecia) ...

7. Lichen planus - Symptoms and causes - Mayo Clinic

   Lichen planus (LIE-kun PLAY-nus) is a condition of the skin, hair, nails, mouth and genitals. On skin, lichen planus often appears as purple, itchy, flat bumps ...

8. Clinical Study Of Oral CMET Inhibitor INC280 In Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer

   Patients with any grade of alopecia are allowed to enter the study. Patients must have adequate organ function; ECOG performance status (PS) of 0 or 1 ...

9. An Expanded Access Study of Iniparib Combined with Gemcitabine and Carboplatin for the Treatment of Breast Cancer - Mayo Clinic

   ... alopecia, related to anticancer therapy prior to the first dose of study drug; Major medical conditions that might affect EAP participation (e.g. ...

10. Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer - Mayo Clinic

    Patients should have resolution of any toxic effects of prior therapy (except alopecia) to National Cancer Institute (NCI) Common Terminology Criteria for ...